A highly-anticipated scientific paper has landed! This new work challenges current theories in Huntington’s disease research, uncovering how runaway CAG repeats erode cell identity in certain types of brain cells, leading to their death.
Researchers have detected early changes in brain scans and biomarkers in young people with the Huntington’s disease gene, 20 years before symptoms are predicted to appear. These findings could help develop medicines to treat HD earlier in life.
Cell replacement therapy is making massive strides for other diseases. But what about Huntington’s disease? Can we use technological advancements in this area to replace lost brain cells with the hope of repairing and reversing disease?
Apathy in Huntington’s disease isn’t just a lack of motivation—it’s a shift in how the brain weighs decisions. A new study sheds light on how targeted treatments could help restore motivation and improve quality of life.
As we begin 2025, we look back on all of the Huntington’s disease research news and progress the field has made in the last 12 months.
We’re proud to announce AJ Keefe as our last HDBuzz Prize winner of 2024! Our cells are an intricate choreography between various molecular dancers. Knowing who moves well with whom, and how that changes with disease, could help advance drugs for HD.
Vico Therapeutics have shared interim data about their drug, VO659, which targets the CAG expansion that causes several genetic diseases, including #Huntingtonsdisease and #spinocerebellarataxia
In an update shared today, uniQure announced alignment with the US drug regulator on key criteria for accelerated approval of drugs for Huntington’s disease.
A new Phase 1 clinical trial for the huntingtin-lowering drug ALN-HTT02 was initiated this week with the first dose given. Read on to learn details about the trial and how it compares to other ongoing huntingtin-lowering trials in the clinic.